{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:53:09Z","timestamp":1785541989038,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40263-019-00662-y","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:55:36Z","timestamp":1569920136000},"page":"971-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Meta-Analysis of Placebo Response in Adult Antidepressant Trials"],"prefix":"10.1007","volume":"33","author":[{"given":"Fenghua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeeha","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Olten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-4080","authenticated-orcid":false,"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"issue":"9904","key":"662_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575\u201386.","journal-title":"Lancet."},{"issue":"10","key":"662_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/da.20355","volume":"25","author":"A Bose","year":"2008","unstructured":"Bose A, Korotzer A, Gommoll C, Li D. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008;25(10):854\u201361.","journal-title":"Depress Anxiety."},{"issue":"5","key":"662_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/da.20695","volume":"27","author":"V Coric","year":"2010","unstructured":"Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010;27(5):417\u201325.","journal-title":"Depress Anxiety."},{"issue":"4","key":"662_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00004850-200307000-00003","volume":"18","author":"UM Lepola","year":"2003","unstructured":"Lepola UM, Loft H, Reines EH. Escitalopram (10\u201320\u00a0mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18(4):211\u20137.","journal-title":"Int Clin Psychopharmacol."},{"issue":"4","key":"662_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1185\/030079907X178838","volume":"23","author":"DJ Stein","year":"2007","unstructured":"Stein DJ, Wreford Andersen E, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23(4):701\u201311.","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"662_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4088\/JCP.10m06191","volume":"72","author":"NA Khin","year":"2011","unstructured":"Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72(4):464\u201372.","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"662_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","volume":"170","author":"BR Rutherford","year":"2013","unstructured":"Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723\u201333.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"662_CR8","first-page":"128","volume":"222","author":"I Kirsch","year":"2014","unstructured":"Kirsch I. Antidepressants and the placebo effect. Z Psychol. 2014;222(3):128\u201334.","journal-title":"Z Psychol."},{"issue":"4","key":"662_CR9","first-page":"211","volume":"191","author":"A Khan","year":"2003","unstructured":"Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211\u20138.","journal-title":"J Nerv Ment Dis."},{"issue":"3","key":"662_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","volume":"2","author":"K Weimer","year":"2015","unstructured":"Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry. 2015;2(3):246\u201357.","journal-title":"Lancet Psychiatry."},{"issue":"11","key":"662_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","volume":"3","author":"TA Furukawa","year":"2016","unstructured":"Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059\u201366.","journal-title":"Lancet Psychiatry."},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jad.2017.03.024","volume":"215","author":"R Meister","year":"2017","unstructured":"Meister R, Jansen A, H\u00e4rter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder: a meta-regression analysis. J Affect Disord. 2017;215:288\u201398.","journal-title":"J Affect Disord."},{"issue":"11","key":"662_CR13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.4088\/JCP.v67n1111","volume":"67","author":"DJ Stein","year":"2006","unstructured":"Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741\u20136.","journal-title":"J Clin Psychiatry."},{"issue":"8","key":"662_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","volume":"161","author":"JD Huppert","year":"2004","unstructured":"Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JR, Gorman JM, et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry. 2004;161(8):1485\u20137.","journal-title":"Am J Psychiatry."},{"issue":"8","key":"662_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0006-3223(99)00311-X","volume":"47","author":"PE Keck Jr","year":"2000","unstructured":"Keck PE Jr, Welge JA, McElroy SL, Arnold LM, Strakowski SM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry. 2000;47(8):748\u201355.","journal-title":"Biol Psychiatry."},{"issue":"1","key":"662_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaac.2010.10.008","volume":"50","author":"MM Reyes","year":"2011","unstructured":"Reyes MM, Panza KE, Martin A, Bloch MH. Time-lag bias in trials of pediatric antidepressants: a systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(1):63\u201372.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"12","key":"662_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014;71(12):1409\u201321.","journal-title":"JAMA Psychiatry."},{"issue":"Suppl.","key":"662_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13651500410005513","volume":"8","author":"D Nutt","year":"2004","unstructured":"Nutt D. Anxiety and depression: individual entities or two sides of the same coin? Int J Psychiatry Clin Pract. 2004;8(Suppl.):19\u201324.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3","key":"662_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","volume":"165","author":"M Fava","year":"2008","unstructured":"Fava M, Rush AJ, Alpert JE, Balasubramani G, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342\u201351.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"662_CR20","doi-asserted-by":"publisher","first-page":"91S","DOI":"10.1016\/S0893-133X(99)00036-6","volume":"21","author":"P Blier","year":"1999","unstructured":"Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999;21(2):91S\u20138S.","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"662_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1177\/003151259508100264","volume":"81","author":"RP Greenberg","year":"1995","unstructured":"Greenberg RP, Fisher S, Riter JA. Placebo washout is not a meaningful part of antidepressant drug trials. Percept Mot Skills. 1995;81(2):688\u201390.","journal-title":"Percept Mot Skills."},{"issue":"2","key":"662_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jpsychores.2004.08.011","volume":"58","author":"AL Geers","year":"2005","unstructured":"Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res. 2005;58(2):121\u20137.","journal-title":"J Psychosom Res."},{"issue":"10","key":"662_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","volume":"74","author":"C Locher","year":"2017","unstructured":"Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin\u2013norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(10):1011\u201320.","journal-title":"JAMA Psychiatry."},{"issue":"1\u20133","key":"662_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","volume":"118","author":"W Rief","year":"2009","unstructured":"Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1\u20133):1\u20138.","journal-title":"J Affect Disord."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00662-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T23:14:23Z","timestamp":1601421263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00662-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00662-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"1 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael H. Bloch receives research support from Therapix Biosciences, Neurocrine Biosciences, Janssen Pharmacueticals, and Biohaven Pharmaceuticals. He also gratefully acknowledges additional research support from NIH, NARSAD, and the Patterson Foundation. Fenghua Li, Madeeha Nasir, and Baris Olten have no conflicts of interest that are directly relevant to the content of this article. This article was completed in compliance with the recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals\u2019 issued by the International Committee for Medical Journal Editors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}